Intellectual Product
ASCO25 Primer: Navigating Cancer R&D Amid Regulatory Uncertainty
ASCO25; cancer research; oncology; regulatory uncertainty; immunotherapy; precision medicine; diagnostics; expert perspectives; policy changes
RFK Jr. Defends HHS Staff Cuts and Reorganization at House and Senate Hearings
RFK Jr.; HHS; staff cuts; reorganization; Congress; House Appropriations Committee; Senate HELP Committee; budget cuts; Medicaid; health coverage
Federal Appeals Court Revives CRISPR Patent Dispute Between Broad Institute and University of California
CRISPR; patent dispute; Broad Institute; University of California; Federal Circuit; PTAB; gene editing; intellectual property; eukaryotic cells
White House Threatens Most Favored Nation Plan to Lower US Drug Prices, but Many Questions Remain
Most Favored Nation; drug pricing; White House; executive order; prescription drugs; Trump administration; US drug prices; global price comparison; pharmaceutical policy
Trump’s Drug Pricing Order Raises Questions of Effectiveness
Trump; Drug Pricing; Executive Order; Most-Favored-Nation Pricing
Roche could rethink $50B US expansion plan if new policies ‘harm’ operations
Roche (company), United States, Investments, expansion, Policy, Infantile Neuroaxonal Dystrophy
Trump signs sweeping executive order to cut US drug prices by ‘up to 90%’
Prices, HHS, United States, Transplant Registry Unified Management Program, Policy
Vinay Prasads FDA Appointment Anything but Status Quo
United States Food and Drug Administration, Appointments, Vaccines, Prasad, Prasad ‘s, Anything, Status Quo
In first oncology expert meeting under Makary, FDA spotlights cancer drugs from J&J, Pfizer, Roche and UroGen
United States Food and Drug Administration, oncology expert, J&J, Pfizer, Roche (company), UroGen
From deal to disaster: Drugmakers face a changed Washington as Trump embraces most favored nation prices
Prices, Transplant Registry Unified Management Program, MFN, Nation, Disasters, Medicaid, Policy, drugmakers, U.S.